ArticleJCO precision oncology2022

Durable Response to Combined Osimertinib and Pralsetinib Treatment for Osimertinib Resistance Due to Novel Intergenic

Edyta M Urbanska et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.